BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.nebraska.edu

Clinical Trials

Heading Off Peripheral Neuropathy With Exercise

Not Applicable

Terminated

Conditions: Breast Neoplasms
Chemotherapy
Peripheral Nervous System Disorders

Interventions: Behavioral: Aerobic/ Resistance Exercise Intervention
Behavioral: Attention control

First Posted Date: 2009-03-26

Last Posted Date: 2023-12-05

Lead Sponsor: University of Nebraska

Target Recruit Count: 19

Registration Number: NCT00869804

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Clearance of NNAL and Cotinine From Second-hand Smoke in Hair and Urine

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2009-03-18

Last Posted Date: 2023-08-14

Lead Sponsor: University of Nebraska

Registration Number: NCT00863824

Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus

Terminated

Conditions: Staphylococcus Aureus

First Posted Date: 2009-03-17

Last Posted Date: 2023-08-23

Lead Sponsor: University of Nebraska

Target Recruit Count: 250

Registration Number: NCT00862862

Locations: 🇺🇸
Unversity of Nebraska Medical Center, Omaha, Nebraska, United States

Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging

Completed

Conditions: Heart Disease
Kawasaki Disease

First Posted Date: 2009-03-16

Last Posted Date: 2023-09-25

Lead Sponsor: University of Nebraska

Target Recruit Count: 124

Registration Number: NCT00861848

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer

Phase 1

Completed

Conditions: Recurrent Small Cell Lung Carcinoma

Interventions: Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Drug: Topotecan Hydrochloride

First Posted Date: 2009-03-05

Last Posted Date: 2023-09-26

Lead Sponsor: University of Nebraska

Target Recruit Count: 22

Registration Number: NCT00856037

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Regadenoson R-T Perfusion Imaging Trial

Phase 1

Completed

Conditions: Coronary Artery Disease
Myocardial Perfusion Abnormalities

Interventions: Drug: Regadenoson

First Posted Date: 2009-02-05

Last Posted Date: 2024-12-27

Lead Sponsor: University of Nebraska

Target Recruit Count: 100

Registration Number: NCT00837369

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
University of Nebraska Medicial Center, Omaha, Nebraska, United States

Arteriovenous Fistula Tissue Bank for Pre- and Post-Fistula Placement Specimens

Completed

Conditions: Kidney Failure, Chronic

Interventions: Other: Biologic specimens

First Posted Date: 2009-02-04

Last Posted Date: 2023-12-28

Lead Sponsor: University of Nebraska

Target Recruit Count: 43

Registration Number: NCT00836862

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Vascular Changes Following Forearm Loop Arteriovenous Graft Placement

Completed

Conditions: Chronic Kidney Disease

First Posted Date: 2009-02-04

Last Posted Date: 2023-09-14

Lead Sponsor: University of Nebraska

Target Recruit Count: 10

Registration Number: NCT00836563

Locations: 🇺🇸
University of Nebraska Medical Center/The Nebraska Medical Center, Omaha, Nebraska, United States

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

Phase 2

Completed

Conditions: Parenteral Nutrition Associated Liver Disease PNALD
Cholestasis

Interventions: Drug: Omegaven™

First Posted Date: 2009-01-21

Last Posted Date: 2023-10-05

Lead Sponsor: University of Nebraska

Target Recruit Count: 72

Registration Number: NCT00826020

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Phase 1

Withdrawn

Conditions: Nonmalignant Neoplasm
Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes
Lymphoma

Interventions: Drug: cyclosporine
Drug: mycophenolate mofetil
Drug: pentostatin
Genetic: cytogenetic analysis
Genetic: fluorescence in situ hybridization
Genetic: protein analysis
Other: flow cytometry
Other: immunoenzyme technique
Other: laboratory biomarker analysis
Other: reduced-intensity transplant conditioning procedure
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation (PBSC)
Radiation: total-body irradiation

First Posted Date: 2009-01-01

Last Posted Date: 2023-08-14

Lead Sponsor: University of Nebraska

Registration Number: NCT00816413

AI-Powered Research

Premium Access

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

Heading Off Peripheral Neuropathy With Exercise

Clearance of NNAL and Cotinine From Second-hand Smoke in Hair and Urine

Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus

Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging

Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer

Regadenoson R-T Perfusion Imaging Trial

Arteriovenous Fistula Tissue Bank for Pre- and Post-Fistula Placement Specimens

Vascular Changes Following Forearm Loop Arteriovenous Graft Placement

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer